Fig 1: Cytotoxicity and proliferation of CD38 CAR-T cells in vitro. (A) The ability of CAR-T cells to kill tumor cells was measured by luciferase assay. CD38 CAR-T cells or pan-T cells were incubated with RPMI-gfp-luc cells or Raji-luc cells, and the luciferase signal was determined after 12 hours. (B) The ability of CAR-T cells to kill tumor cells was measured by an IncuCyte S3 system. RPMI-gfp-luc cells were incubated with CD38 CAR-T cells or pan-T cells at an E:T ratio of 1:1. Total integrated GFP intensity per well was assessed as a quantitative measure of live, GFP+ tumor cells. The values were normalized to the starting values. (C) The ability of CD38 CAR-T cells to kill tumor cells was determined by flow cytometry. CD38 CAR-T cells or pan-T cells were incubated with RPMI-gfp-luc cells, Raji-luc cells, Daudi cells or K562-hBCMA cells for 12 hours. (D) CD38 CAR-T cells were incubated with RPMI-gfp-luc cells for 12 hours, and the secretion of cytokines was measured with a flow cytometry-based CBA kit. The graph shows the secretion of TNFa, IFN-?, IL-2 and granzyme B. (E) The proliferation of CD38 CAR-T cells. The proliferation ability was measured by the CFSE-based assay. Data were obtained from three replicates and are presented as the mean ± SEM (n=3). *indicates p value < 0.05; **< 0.01; ***< 0.005 and ****< 0.001, comparison of two groups was performed by Student’s t-test. TNF-a, tumor necrosis factor a; IFN-?, interferon ?; IL-2, interleukin 2.